Nasus Pharma Ltd financial metrics

Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic. Latest period: Q4 2025.

Public ticker
NSRX on NYSE
Latest financial report
25 Mar 2026
Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
Tel Aviv Yafo, Israel
SEC filing record 1 source field available
Fiscal year end
31 December

Shareable Research Card

NSRX - Nasus Pharma Ltd Financial Facts

NSRX - Nasus Pharma Ltd has a source-backed company facts page for reviewing reported financial metrics, periods, and linked metric histories.

Start with the latest metric summary, then open metric histories or cross-company rankings to compare the same SEC-backed facts.

Context
Latest metrics period: Q4 2025
Latest reported value
Current Ratio 2.24x

Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open metric pages to inspect the reported history.

Open stable link Open latest 10-Q/10-K hub

Return Loop

Why revisit this company facts page

Company facts change as new 10-Q and 10-K filings update the latest reported period, headline values, and cross-company comparison context.

Latest source-backed update
Latest metrics period Q4 2025
Why come back
Use the next filing cycle to compare new facts against this baseline and then verify the detailed metric history.
  • Current latest metrics period: Q4 2025.
  • Most recent SEC facts end date on this page: 31 Dec 2025.
  • Save this filer to return when the next filing-backed metric period changes the picture.

Freshness comes from the latest SEC company facts period available for this filer and the linked metric history pages.

Create account to save this filer Open latest 10-Q/10-K hub

Latest update

Latest update for NSRX - Nasus Pharma Ltd

New fact period available

Latest financial period: Q4 2025. Reopen this facts page to verify the newest reported period against the prior baseline.

Update date

25 Mar 2026

Page type

Company facts

Latest period

Q4 2025

SEC-backed company facts were refreshed from filings filed on 25 Mar 2026.

Open recent updates hub Open latest 10-Q/10-K hub

Benchmark Context

How Current Ratio compares

Current Ratio is up about 1830% versus the comparable prior period.

Compared with

Compared with Nasus Pharma Ltd's recent history first. Same-industry peer context appears only when enough SEC-backed benchmark coverage exists.

Why this is notable

Current Ratio already has a self-history signal here, but same-industry benchmark context waits until the benchmark sample is strong enough.

  • Latest comparable period on this page: Q4 2025.
  • Peer context will appear when enough companies report a comparable value for this metric.
  • Open the metric history first if you want to verify the exact period-to-period change.

Industry benchmark context uses SEC-reported values from the same methodology version. Latest periods may differ across companies.

Open latest 10-Q/10-K hub

Save this filer page

Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.

Create free account and save this filer Already have an account? Sign in and save it

Key facts

  • NSRX - Nasus Pharma Ltd financial facts are built from SEC company filings data.
  • Latest metrics period on this page: Q4 2025.
  • Headline metric: Current Ratio 2.24x.

Change

  • Current Ratio YoY change: +1830%.
  • Most recent SEC facts end date: 31 Dec 2025.

Research use

  • This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
  • Every metric card links to a deeper SEC-backed history page for verification.

Evidence

Based on latest 10-Q/10-K

Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open company facts to inspect the reported metric history.

View source filing

Latest SEC snapshot (2025-12-31) highlights Current Ratio 2.24x.

Valuation Snapshot

Simple DCF estimate from SEC company facts, using free cash flow, cash, debt, and reported share count when available.

DCF value materially below price

-375%

fair value gap

Fair value per share

$8.81

Market price

$3.20

NSRX - Local security

PEG ratio

n/a

Enterprise value

$71.83M

Equity value

$70.59M

Key valuation metrics

EV/Revenue

0.0x

Local security market EV / SEC revenue

EV/EBITDA

n/a

Local security market EV / SEC EBITDA

Ebitda is unavailable or not positive

P/E

n/a

Local security market price / SEC EPS

Net income is unavailable or not positive

P/S

0.0x

Local security market cap / SEC revenue

P/B

9.3x

Local security market cap / SEC equity

PEG

n/a

P/E / DCF Growth Assumption

P/e or positive growth is unavailable

Core assumptions

Projection
5 years
FCF growth
4%
Discount rate
10%
Terminal growth
2.5%

SEC fact inputs

Free cash flow
$4.93M
Net income
$5.86M
EBITDA
n/a
Cash
$1.24M
Debt
n/a
Equity
$2.77M
Shares
8,010,126

Data confidence notes

  • Debt missing: equity value treats debt as 0
  • Base free cash flow is negative; dcf output is mechanically computed but high risk
  • Peg unavailable: earnings per share is not positive

Financial Quality Score

Transparent 0-100 scoring model based on profitability, financial health, and growth factors.

89.1/100

Strong Confidence low

Financial Health

Current Ratio
2.24x

Strengths

Current Ratio

Watchpoints

No major risk flags from available metrics.

Key metrics snapshot

Financial Health

Metric Latest value YoY change
Current Ratio 2.24x +1830%

Share Metrics

Metric Latest value YoY change
Entity Common Stock, Shares Outstanding 9,015,383
Common Stock, Shares, Outstanding 9,015,383 +22%

Supporting Metrics

These supporting metrics stay fully source-backed for deeper research. Scan the latest value and reported period first, then open a metric page when you need the full filing trail.

Metric Latest value YoY change
Accounts Payable, Current $829,000 +27%
Accrued Liabilities, Current $553,000 -34%
Additional Paid in Capital $21,288,000 +126%
Assets $5,004,000 +598%
Assets, Current $4,855,000 +962%
Cash and Cash Equivalents, at Carrying Value $1,237,000 +336%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1,291,000 +315%
Common Stock, Par or Stated Value Per Share 0 -100%
Common Stock, Shares Authorized 22,801,942 +72%
Common Stock, Shares, Issued 9,015,383 +22%
Deferred Tax Assets, Gross $3,344,000 +42%
Deferred Tax Assets, Operating Loss Carryforwards $2,952,000 +31%
Deferred Tax Assets, Valuation Allowance $3,344,000 +42%
Employee-related Liabilities, Current $233,000 +566%
Lessee, Operating Lease, Liability, to be Paid $147,000
Lessee, Operating Lease, Liability, to be Paid, Year One $53,000
Lessee, Operating Lease, Liability, to be Paid, Year Three $41,000
Lessee, Operating Lease, Liability, to be Paid, Year Two $53,000
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $29,000
Liabilities $2,236,000 -43%
Liabilities and Equity $5,004,000 +598%
Liabilities, Current $2,163,000 -45%
Operating Lease, Liability $118,000
Operating Lease, Liability, Current $45,000
Operating Lease, Liability, Noncurrent $73,000
Operating Lease, Right-of-Use Asset $135,000
Operating Lease, Weighted Average Discount Rate, Percent 0.08
Other Assets, Current $186,000 +541%
Property, Plant and Equipment, Net $14,000
Retained Earnings (Accumulated Deficit) $18,520,000 -46%
Stockholders' Equity Attributable to Parent $2,768,000

How we score

This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.

Metric Weight V1 threshold
ROIC205% to 20%
ROE158% to 25%
ROA102% to 10%
Operating Margin55% to 25%
Current Ratio121.0x to 2.0x
Quick Ratio80.8x to 1.5x
Debt to Equity100.3x to 2.0x (lower is better)
Revenue YoY10-10% to +20%
Net Income YoY10-10% to +20%

How Calculated (standard_v1)

Metrics are computed with a market-consensus convention designed for cross-portal comparability.

  • TTM Operating Income / TTM Revenues
  • Current Assets / Current Liabilities (latest instant quarter)
  • (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
  • Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
  • TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
  • TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
  • TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
  • TTM Revenues YoY
  • TTM Net Income YoY
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .